Eli Lilly's Weight-Loss Drug Zepbound and Diabetes Treatment Mounjaro Drive Record Earnings

The pharmaceutical giant surpasses market expectations with strong Q4 results, buoyed by soaring demand for its obesity and diabetes medications.

Eli Lilly reports a significant revenue increase to $9.35 billion in Q4, with a 28% year-over-year growth.
Zepbound, launched in November, generates $175.8 million in sales, while Mounjaro's sales reach $2.21 billion.
The company's market valuation hits $700 billion, becoming the world's most valuable healthcare company.
Eli Lilly plans to expand manufacturing capacity to meet the high demand for its weight-loss and diabetes drugs.
Analysts predict Zepbound sales could reach $1.9 billion in 2024, with potential growth to $12 billion in the coming years.